font-family: “Helvetica”, sans-serif;
border-width: 4px 0;
border-top: 2px solid #666;
border-bottom: 2px solid #666;
padding: 10px 0;
font-family: “Theinhardt-Medium”, sans-serif;
In a number of critical cases of COVID-19, a hyper-vigilant immune response is triggered in patients that, if untreated, can itself prove fatal. Fortunately, some pharmaceutical treatments are available—although it’s not yet fully understood how well they might work in addressing the new coronavirus.
Meanwhile, a new blood filtration technology has successfully treated other, similar hyper-vigilant immune syndromes for people who underwent heart surgeries and the critically ill. Which could make it a possibly effective therapy (albeit still not FDA-approved) for some severe COVID-19 cases.
Inflammation, says Phillip Chan—an M.D./PhD and CEO of the New Jersey-based company CytoSorbents—is the body’s way of dealing with infection and injury. It’s why burns and sprained ankles turn red and swell up. “That’s the body’s way of bringing oxygen and nutrients to heal,” he said.